Nightingale Health Plc and 23andMe Holding Co. announced a strategic collaboration to pilot Nightingale Health?s clinically-validated and cost-effective blood metabolomics panel with a cohort of 23andMe members. Nightingale?s Remote Health Check accurately measures dozens of biomarkers from a single blood sample, including cholesterols, apolipoproteins and fatty acids like omega-3. Many of these blood biomarkers have established clinical relationships to disease and can help guide important lifestyle interventions ?

such as diet and exercise. This pilot marks an important milestone in making blood testing more efficient and accessible. 23andMe currently offers its annual members the option for blood testing and provides interactive tools like HealthTracks, a feature that incorporates customer lifestyle choices into calculating a lifetime risk of disease.

Blood biomarkers may improve the accuracy of these predictions and provide more direct insight into the kinds of interventions that may be most impactful to a customer?s health. As part of the pilot, 23andMe will offer up to 5,000 23andMe+ Premium and Total Health members the opportunity to receive blood testing through Nightingale?s Remote Health Check at no cost to them. The pilot will evaluate customer feedback around blood testing, at-home sample collection, and the utility of the data when coupled with 23andMe?s established personal genetics products.

23andMe and Nightingale Health have a shared vision to help individuals identify health risks and prevent disease through proactive testing, treatment, coaching and behavior change. Together, the companies? technologies allow for a more comprehensive assessment of a customer?s health and continuous tracking of progress toward their goals.